All Stories

  1. Glutathione antioxidant pathways in patients with schizophrenia: relationship with metabolic syndrome
  2. Polymorphic variants of proinflammatory cytokine genes in affective disorders and in cases of comorbidity with alcohol addiction
  3. Clinical example of delayed chronic psychosis in the form of hallucinosis in a patient with 1,4-butanediol dependence
  4. The Impact of Psychiatric Comorbidity on the Clinical Manifestations and Severity of Posttraumatic Stress Disorder
  5. Modern Diagnostics of Borderline Personality Disorder: the Relationship between Categorical and Dimensional Approaches
  6. Protein Kinase Expression of the AKT/mTOR Signaling Pathway in Peripheral Mononuclear Cells of Schizophrenia Patients: A Pilot Study
  7. Diagnosis of anxiety and depressive states in alcohol dependence: agreement between clinical assessment and patient self-assessment
  8. Myeloperoxidase, Cathepsin D, and Plasminogen Activation Inhibitor Type 1 as Potential Biomarkers of Schizophrenia (pilot study)
  9. Аминодигидрофталазиндион натрия в комплексной терапии пациентов с алкогольной зависимостью
  10. Predicting the risk of the formation of mixed anxiety and depressive disorders in women
  11. Quantitative electroencephalogram in females at different stages of alcohol remission
  12. Suicidal risk in bipolar affective disorder taking into account its comorbidity with alcohol addiction
  13. Клинические, социальные и психологические факторы эффективности становления ремиссии при алкогольной зависимости
  14. Academic Psychiatric School in Siberia: History of Formation and Horizons of Development. Interview with an Academician of RAS Nikolay A. Bokhan
  15. COVID-19 anxiety predicts loneliness among university students: the mediating roles of mattering, fear of not mattering, and anti-mattering
  16. The impact of the hypothalamic-pituitary-thyroid axis hormone levels on suicide risk in patients with schizophrenia
  17. Иммунобиологическая модель диагностики течения расстройства адаптации у женщин
  18. Исследование влияния технологии виртуальной реальности на психоэмоциональное состояние здоровых добровольцев
  19. The influence of gender on the clinical and dynamic indicators of alcohol dependence, the level of aggression of patients taking into account comorbidity with affective disorders
  20. Influence of Comorbidity of Depressive Disorders with Alcohol Dependence on the Main Clinical and Dynamic Characteristics of Depression and the Manifestations of Aggressiveness
  21. Indicators of the background spectral power of the EEG in patients with alcohol dependence complicated by exogenous organic brain disease
  22. Features of structural and functional changes of the brain in patients with schizophrenia
  23. Phenotypic Characteristics of Peripheral Blood Lymphocytes in Patients with Alcohol Dependence in the Dynamics of the Post-Abstinence State
  24. Influence of pharmacotherapy on function of biotransformation of xenobiotics liver in patients with neuropsychiatric disorders
  25. Cariprazine in Hospital Treatment of Acute Psychotic Conditions Due to Comorbid Schizophrenia and Chemical Addictions
  26. Association of Peripheral Markers of Oxidative Stress with Clinical Parameters and Inflammatory Factors in Alcoholic Patients
  27. Alcohol-Induced Activation of Chemokine System and Neuroinflammation Development
  28. Halonal, an original benzoylated phenobarbital derivative anticonvulsant: in vivo evaluation, chemometric and molecular docking studies of enantiomers
  29. Иммунологические маркеры прогнозирования затяжного течения расстройства адаптации у женщин с гипотиреозом
  30. Взаимосвязь тромбоцитарных факторов роста с клиническими и клинико-динамическими характеристиками у пациентов с аффективными расстройствами
  31. Features of the Background EEG of Alcohol Dependent Patients with Comorbid Exogenous Organic Brain Damage
  32. Prevalence and risk factors of non-suicidal self-injury behavior
  33. The relationship between the functional state of the brain and clinical and constitutional factors in schizophrenia
  34. Cerebral hemodynamic disorders in patients with schizophrenia with concomitant metabolic syndrome
  35. Electroencephalographic differences in patients with paranoid schizophrenia with or without a history of suicide attempts
  36. Перекрёстное психометрическое исследование пациентов с параноидной шизофренией с наличием или отсутствием суицидальных попыток в анамнезе
  37. Этнокультуральные исследования в Сибири и на Дальнем Востоке (25 лет Международной ассоциации этнопсихологов и этнопсихотерапевтов)
  38. Sleep structure in adults with recurrent epileptic seizures of remote symptomatic etiology
  39. NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia
  40. Pilot Study of the DRD3, GHRL, FTO, LEPR, INSIG2, GSTP1, and ABCB1 Gene Expression in Peripheral Blood Leukocytes in Schizophrenic Patients with Metabolic Syndrome
  41. Untargeted Plasma Metabolomic Profiling in Patients with Depressive Disorders: A Preliminary Study
  42. The effectiveness of the original anticonvulsant Galodif® — a GABAA receptor modulator for alcohol withdrawal syndrome
  43. Иммунобиологическая модель дифференциальной диагностики расстройства адаптации и органического эмоционально лабильного расстройства
  44. Influence of Alcohol Dependence on the Clinical and Dynamic Characteristics of Bipolar Disorder with Their Comorbidity in Psychiatric Hospital Patients
  45. Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia
  46. Growth factors PDGF-AA, PDGF-BB and BDNF as potential differentiating biomarkers of unipolar and bipolar depression
  47. A pilot study of associations of markers of glial and neuronal degeneration with executive functions in alcohol use disorders
  48. COMPARATIVE ANALYSIS OF ALCOHOL DEPENDENCE AND COGNITIVE DISORDERS IN WOMEN ACROSS DIVERSE ETHNIC POPULATIONS
  49. Innovative Technology of the Self-Emulsifying Drug Delivery System of the Anticonvulsant Galodif
  50. Mental disorders in cerebral paroxysms of epileptic origin
  51. Hormones, oxidized proteins, and lipids in alcoholism. Duration of remission
  52. Development of alcohol dependence and cognitive functioning impairments in women of Tuvan and Russian ethnicity
  53. Динамика алкоголизма в Сибирском и Дальневосточном регионах в зависимости от доходов потенциальных потребителей (1999-2019 гг.)
  54. Клиническая характеристика проявлений боевой психической патологии у комбатантов
  55. An Innovative Stress-Protective and Detoxification Substance for Reducing the Central Nervous System Effects of Alcohol Intoxication
  56. EEG alpha band characteristics in patients with a depressive episode within recurrent and bipolar depression
  57. Relationship of Neurospecific Serum Proteins with Clinical Features in Depressive Episode and Recurrent Depressive Disorder
  58. Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders
  59. Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression, Schizophrenia and Bipolar Disorder
  60. Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
  61. A novel urea derivative anticonvulsant: In vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers
  62. Миграционные потоки: транскультуральные аспекты психического здоровья (обзор зарубежной литературы)
  63. Оценка уровня реабилитационного потенциала у пациентов с психозами, ассоциированными с употреблением современных синтетических психоактивных веществ
  64. EEG Frontal Asymmetry in Unipolar and Bipolar Depression
  65. Genome-wide gene expression responses to experimental manipulation of Saccharomyces cerevisiae repressor activator protein 1 (Rap1) expression level
  66. Когнитивная копинг-терапия алкогольной зависимости и невротических расстройств у пациентов с суицидальными мыслями
  67. Формирование нейрональных элементов нейроиммунной системы эмбрионального мозга человека при пренатальном влиянии алкоголя
  68. Serum Growth Factors in Schizophrenia Patients
  69. Incidence Rate of Nicotine Addiction in University Students of Tomsk
  70. Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
  71. Neurospecific Proteins as Transdiagnostic Markers of Affective Disorders
  72. The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
  73. Association of Non-Suicidal Self-Harm with Anxiety, Depression and Aggressive Behavior in Young Men of Military Age
  74. Treatment of Acute Drug-Induced Psychoses, Associated with Modern Synthetic Psychoactive Substances
  75. Coherence of the electroencephalogram and peripheral markers of nerve tissue damage in depressive disorders
  76. Disorders of cognitive decision-making mechanisms related to reward in alcohol use disorders
  77. Features of the reward-based decision-making in patients with alcohol use disorders
  78. Structural changes in human brain tissue during prenatal alcoholization at different stages of intrauterine development
  79. Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
  80. Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
  81. Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
  82. https://svpin.org/index.php/menujournal-ru/62-zhurnal-za-2022-god/stati-za-2022-god/489-osobennosti-psikhologicheskogo-reagirovaniya-meditsinskikh-rabotnikov-psikhiatricheskogo-statsionara-na-izmenenie-uslovij-professionalnoj-deyatelnosti-v-stressornoj...
  83. Реабилитация в аддиктивных психотерапевтических сообществах психически больных с коморбидным злоупотреблением синтетическими каннабиноидами
  84. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity
  85. The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
  86. The habenular volume and PDE7A allelic polymorphism in major depressive disorder: preliminary findings
  87. Comorbid Mental Disorders and Quality of Life in Patients with Social Phobia
  88. Late Diagnostics of Bipolar Disorder: Impact on Main Characteristics of Disease, Suicidal Behaviour and Social Adaptation Level of Patients
  89. Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
  90. Факторы риска суицидального поведения при биполярном аффективном расстройстве
  91. Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
  92. Cytokine Production in Whole Blood Cells Culture of Patients with Alcohol Dependence and Autologous Plasma Oxidative Stress Markers
  93. Психологические факторы, наносящие транснациональный урон общественному психическому здоровью населения в период пандемии
  94. Возможные нейрофизиологические маркеры для дифференциальной диагностики биполярных и униполярных аффективных расстройств
  95. Формирование алкогольной зависимости у женщин тувинской и русской этнической принадлежности
  96. Anhedonia as target symptom in personalized therapy of patients with mood disorders and alcohol use disorder comorbidity
  97. Anxiety level and EEG indicators in alcohol dependence: a model for predicting the duration of therapeutic remission
  98. Cerebral hemodynamics and executive functioning in patients with alcohol use disorders
  99. Cognitive features of patients with bipolar disorder in comorbidity with alcohol use disorders
  100. Current methods for predicting therapeutic response in patients with depressive disorders
  101. Frequency of interictal epileptiform discharges in slow sleep with relapse of tonic-conical seizures in adults with generalized epilepsy after withdrawal of antiepileptic drugs
  102. Quantitative characteristics of the alpha-band of the electroencephalogram in people with alcohol dependence
  103. The differential diagnosis of unipolar and bipolar depression based on EEG signals
  104. A New Paradigm to Indicate Antidepressant Treatments
  105. Quantitative characteristics of the alpha-rhythm of the electroencephalogram in depressive disorders
  106. Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression
  107. P.0007 Concentration of BDNF and NSE in blood serum of patients with alcohol use disorder with and without comorbid mood disorders
  108. P.0579 Pharmacogenetic study to elucidate putative dopaminergic mechanisms of antidepressant action
  109. Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
  110. Estimation of the effect of lithium salts on cytokine production by blood cells in in vitro experiments
  111. Incidence rate and clinical characteristics of seasonal affective disorders in senior medical students
  112. Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
  113. Bipolar Disorder: Comorbidity with Other Mental Disorders
  114. Clinical-Dynamical Features of Alcohol Use Disorder and Mood Disorders Considering the Chronology of Their Comorbidity Formation
  115. Показатели иммунитета, тревожность и соматическая патология как факторы формирования затяжного течения панического расстройства
  116. Психическое здоровье семьи: научно-исторический контекст и актуальные исследования томских ученых
  117. Correlation of Antibodies to Neurotransmitters in the Sera of Women with Alcohol Dependence and Depressive Disorders
  118. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
  119. Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
  120. Влияние исполнительного функционирования на суицидальное поведение при коморбидности алкогольной зависимости и аффективных расстройств
  121. Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
  122. Clinical characteristics and efficiency of antidepressant therapy of mood disorders with comorbid alcohol use disorder
  123. Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
  124. Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
  125. Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness
  126. Mental Disorders Associated with the Abuse of Synthetic Cannabinoids (Spices)
  127. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
  128. An innovative anticonvulsant - a GABAA receptor modulator with an alternative mechanism of action and enzyme-inducing detoxifying properties
  129. Biological profile of medical response in alcoholic patients of different ethnic groups in Siberia
  130. Clinical dynamics of anhedonia symptom in mood disorder and in alcohol use disorder
  131. Neuroendocrine factors - predictors of the formation of alcohol dependence and human ecology in various ethnic populations, new approaches to therapy
  132. Психические нарушения, развивающиеся в кризисно-экстремальной ситуации пандемии коронавируса: актуальная проблематика и особенности психолого-психотерапевтического консультирования
  133. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
  134. A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia
  135. An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism
  136. Features of brain activity in alcohol dependence in the task of inhibitory control
  137. Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
  138. ALCOHOL DEPENDENCE OCCURRENCE AND COGNITIVE COPING PREVENTIONIN STUDENTS AND YOUNG SPECIALISTS
  139. Cognitive impairment in patients after COVID-19
  140. DYNAMICS OF THE PSYCHOPATOLOGICAL PICTURE OF PSYCHOSIS DEVELOPED IN THE BACKGROUND OF THE CONSUMPTION OF MODERN SYNTHETIC PSYCHOACTIVE SUBSTANCES
  141. Normative Assessment of Cognitive Functions with on the Brief Assessment of Cognition In Schizophrenia (BACS) Scale in the Tomsk Population: Constitutional Factors of Variability
  142. Peripheral Markers of Nervous Tissue Damage in Addictive and Affective Disorders
  143. Possible clinical and electroencephalographic factors for predicting the duration of remission in patients with alcohol dependence
  144. SPATIAL DISTRIBUTION OF BIOPOTENTIALS AND THEIR SOURCES IN BRAIN STRUCTURES IN alcohol-dependent patients WITH COMORBID AFFECTIVE DISORDER
  145. Влияние когнитивных функций на уровень суицидального риска у больных шизофренией
  146. Using the quantitative EEG method in predicting the response to treatment of affective disorders
  147. Взаимосвязь цифровых маркеров онлайн-активности и социально-демографических характеристик лиц призывного возраста с несуицидальными формами самоповреждающего поведения
  148. P.541 Inflammation in schizophrenia with metabolic syndrome: features of the cytokine spectrum
  149. P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients
  150. P.552 Acylcarnitine levels in paranoid schizophrenia with metabolic syndrome during treatment of second-generation antipsychotics
  151. P.514 Contribution of polymorphic variants of MAO genes into prolactin levels in patients with schizophrenia under risperidone therapy
  152. P.182 Metabolic syndrome in patients with schizophrenia and the PTPN5 gene encoding the striatal-enriched protein tyrosine phosphatase
  153. P.513 Metabolic syndrome in schizophrenia and polymorphic variants of CYP1A2 and GSTP1 genes
  154. P.170 Polymorphisms of serotonergic system genes and their association with remission in patients with depression
  155. P.235 S-100, MBP and glial fibrillary acidic protein (GFAP) in patients with mood disorders and alcohol use disorder
  156. P.568 Trihexyphenidyl in combination with antipsychotic therapy does not affect the severity of neurocognitive deficits in patients with schizophrenia
  157. Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
  158. Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
  159. Genetic polymorphisms of PIP5K2A and course of schizophrenia
  160. Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders
  161. Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
  162. Психологические факторы формирования суицидального поведения при обсессивно-компульсивном и социальном тревожном расстройстве
  163. Формирование суицидальности у молодых пациентов с аддиктивными и невротическими расстройствами: социально-психологические факторы риска и психотерапия
  164. NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder
  165. Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
  166. Обзор исследований несуицидальных форм самоповреждений по шкалам и опросникам NSSI
  167. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
  168. 5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
  169. Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression
  170. Affective disorders in comorbidity with alcohol addiction: clinical and dynamic features, social adaptation level of patients
  171. Correction to: Clinical-Dynamic Features of Affective Disorders Comorbid with Alcohol Dependence
  172. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
  173. Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
  174. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
  175. Clinical-Dynamic Features of Affective Disorders Comorbid with Alcohol Dependence
  176. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
  177. Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy
  178. Clinical value of comorbidity of affective disorders and alcohol dependence
  179. Incidence rate of anxiety and personality disorders and their interrelationship in senior-year students of the medical university
  180. Magnetic resonance spectroscopy in Parkinson’s disease
  181. Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
  182. Hormones of stress-response system in alcohol dependence: the ability to predict duration of remission
  183. Relationship of cognitive disorders with clinical features of alcohol dependence
  184. Therapy of patients with breast cancer with anxiety and depressive disorders
  185. WITHDRAWAL SYNDROME IN SYNTHETIC CANNABINOID DEPENDENCE ASSOCIATED WITH MENTAL DISORDERS
  186. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
  187. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients
  188. P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome
  189. P.505 The potential role of BDNF and prolactin genotypes on antidepressant response in depressive patients
  190. P.072 Proteomic approach in schizophrenia and bipolar disorder
  191. P.876 The effect of atypical antipsychotic therapy on hormonal and biochemical parameters in patients with schizophrenia
  192. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
  193. Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
  194. Доля наркозависимых среди завершённых суицидов
  195. Суицидальное поведение больных шизофренией с метаболическим синдромом
  196. Neurocognitive deficits in clinical polymorphism of schizophrenia: typology, expression and syndromal overlaps
  197. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
  198. The difference in serum proteomes in schizophrenia and bipolar disorder
  199. Protective Effects of Pyruvic Acid Salt Against Lithium Toxicity and Oxidative Damage in Human Blood Mononuclear Cells
  200. Суицидальное и парасуицидальное рискованное поведение среди высокообразованной молодежи: дихотомия формирования и дифференцированные возможности когнитивно-поведенческой копинг-терапии
  201. Суицидальные действия наркозависимых: вопросы системного выявления и учёта
  202. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
  203. The Protective Action of Carnosine and Organic Lithium Salts against Ethanol-Induced Oxidative Damage of Blood Plasma Proteins and Lipids of Healthy Persons and Alcoholic Patients
  204. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium
  205. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
  206. SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia
  207. Disorders of spatial working memory in affective disorders with mild current depression and their neurophysiological correlates
  208. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia
  209. Protective action of carnosine and organic lithium salts in case of ethanol-induced oxidative damage of proteins and lipids of blood plasma in healthy persons and alcoholic patients
  210. Apolipoprotein serum levels related to metabolic side effects in patients with schizophrenia
  211. Genes of neurotrophic factors and responsiveness to antidepressive psychopharmacotherapy in patients with depressive disorders
  212. Brain pathology in schizophrenia: association with clinical and constitutional factors
  213. DEVELOPMENT OF ADDICTIVE BEHAVIOR IN ADOLESCENT FEMALE STUDENTS FROM COMPREHENSIVE AND CORRECTIVE BOARDING SCHOOLS
  214. Effects of antipsychotic therapy on lipid and carbohydrate metabolism of schizophrenic patients
  215. NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT
  216. Parameters of immunity and level of cortisol in schizophrenic patients under long-term therapy with risperidone
  217. Prediction of visceral obesity in schizophrenic patients under therapy with antipsychotics
  218. Quantitative assessment of gray matter changes in patients with schizophrenia by MRI approach
  219. Stress hormones in men whose professional activities are either office-based or of an extreme emergency nature
  220. The role of neuroendocrine factors in the formation of alcohol dependence and human ecology in different ethnic populations: new approaches in therapy
  221. Time course of cognitive dysfunction and biochemical marker of CNS lesions S100ß in coronary artery bypass graft
  222. Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy
  223. Связь суицидального поведения и безнадёжности с акатизией у больных шизофренией
  224. Суицидальное поведение больных биполярным аффективным расстройством при коморбидных психических заболеваниях
  225. Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy
  226. IgG antibodies from the sera of patients degrade myelin basic protein
  227. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
  228. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
  229. Depressive disorders in women of climacteric age (review of foreign literature for 2012–2016)
  230. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
  231. Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy
  232. Inflammatory factors and immunophenotypes in adjustment disorders
  233. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine
  234. Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia
  235. Potential biomarkers of tardive dyskinesia: a multiplex analysis of blood serum
  236. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson’s disease
  237. Association of polymorphism in the dopamine receptors and transporter genes with hyperprolactinemia in patients with schizophrenia
  238. Gene polymorphisms of enzymes biotransformation of xenobiotics in patients with depressive disorders
  239. Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
  240. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease
  241. Olfaction, pain sensitivity and immunoendocrine system in substance use disorders
  242. THE BEHAVIOR STRATEGIES IN SITUATIONS OF DISORDER AND MEASURES CONTRIBUTING HEALTH CONDITIONS OF PATIENTS WITH MENTAL ILNESSES COMBINED WITH COMORBID DEPRESSION SYNDROME
  243. Clinical-immunological predictors of prognosis of the efficiency of antipsychotic therapy with amisulpride in schizophrenia
  244. Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders
  245. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics
  246. Association Between Prolactin Gene Polymorphism (–1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia
  247. Biomarkers of depressive disorders: A multiplex analysis of blood serum
  248. Clinical Variants of Psychopathological Disorders in Users of Synthetic Cannabinoids (Spices)
  249. Effect of original anticonvulsant meta-chloro-benzhydryl-urea on behavioral and immune parameters in mice with active and passive behavior types in experimental alcoholism
  250. Effect of Prenatal Exposure to Alcohol on the Development of Brain Vessels in Human Embryos and Fetuses
  251. Evaluation of dynamics of neurocognitive indicators and pathological craving in patients with dependence on synthetic cannabinoids during use of microwave resonance therapy
  252. Factors of premorbid period indicating the risk of medicated noncompliance in patients with schizophrenia
  253. Molecular targets of the ethanol and original anticonvulsant in the treatment of alcohol dependence
  254. Morphophenotypical patterns in patients with negative symptoms in schizophrenia
  255. Women with hysterical manifestations: Menopause, gender and mental health
  256. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders
  257. Association of polymorphic variants of PIP5K2A and HTR2C genes with response to antidepressant therapy of patients with a current depressive episode
  258. Association study of genetic markers of schizophrenia and its cognitive endophenotypes
  259. Gender aspects of medico-social adaptation in adults with early onset of epilepsy
  260. Indices of the antioxidant system and dopamine in blood plasma in the dynamics of microwave resonance therapy in patients with alcoholism
  261. Association of СОМТ gene polymorphisms with Parkinson’s disease
  262. Нейрогуморальные маркеры прогноза эффективности фармакотерапии депрессивных расстройств, "Нейрохимия"
  263. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
  264. Gene polymorphism of neurotransmitter transporters in schizophrenic patients with drug-induced hyperprolactinemia
  265. Gene polymorphism of serotonin receptors and drug-induced hyperprolactinemia in schizophrenic patients
  266. Association of PIP5K2A and SGK1 genes with drug-induced dyskinesia in patients with schizophrenia
  267. CYP2D6 and catechol-O-methyltransferase gene polymorphisms in Parkinson patients with levodopa-induced dyskinesias
  268. Dynamics of neurohumoral factors in patients with depressive disorders in the treatment with selective serotonin reuptake inhibitors
  269. Gene polymorphisms of cytochrome P450, 1A2, 2D6 and drug-induced tardive dyskinesia in Russian patients with schizophrenia
  270. Neurohormonal factors of atypical depression
  271. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
  272. FEATURES OF COGNITIVE RESOURCES OF COPING WITH DIFFICULT LIFE SITUATIONS IN REPRESENTATIVES OF ETHNIC GROUPS OF SIBERIA
  273. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group
  274. Agression of adolescents who comnmit offenses
  275. Cognitive functioning in alcoholic patients and efficiency of their correction with use of individualized therapy
  276. Therapeutic efficacy of original anticonvulsant meta-chloro-benzhydrylurea (m-ch-BHU) in the treatment of patients with a compulsive craving for alcohol
  277. not-labeling of psychiatry and mental patients
  278. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects
  279. Disrupted homeostasis during chronic ethanol consumption associated with specific mechanism of endogenous neurosteroids activity
  280. Neuroleptic effect in aggressive mice after the transplantation of immune cells treated in vitro with chlorpromazine
  281. Russian Federation
  282. Antioxidant and Immunotropic Properties of some Lithium Salts
  283. Treatment of Alcoholic Patients Using Anticonvulsant Urea Derivative Influences the Metabolism of Neuro-active Steroid Hormones - The System of Stress Markers
  284. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies
  285. The Effect of Chronic Alcohol Abuse on the Benzodiazepine Receptor System in Various Areas of the Human Brain
  286. An effect of quetiapine on the immune system of patients with schizophrenia
  287. PSYCHOMETRIC EVALUATION OF SYMPTOMS AND CLINICAL DYNAMICS OF SCHIZOPHRENIA IN DEPENDING ON CONSTITUTIONALLY-MORPHOLOGICAL TYPE OF THE PATIENTS
  288. Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease
  289. The association of the DRD3 gene with Parkinson’s disease
  290. The Influence of Alcohol Addiction on Cognitive Functions of the Representatives of Indigenous Population of Siberia
  291. An association of AKT1 gene polymorphism with antidepressant treatment response
  292. Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy
  293. Association of Cytokine Production with Hormone Level and Sensory Responses during the Formation of Psychoactive Drug Addiction in Men
  294. Association of drd3 gene polymorphisms with parkinson's disease (PD)
  295. Влияние адамантилбромфениламина на параметры иммунитета и симптомы астении у пациентов с непсихотическими психическими расстройствами
  296. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
  297. P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia
  298. P.5.d.005 Polymorphisms of DRD2, DRD3, DRD4 and HTR2C genes in levodopa-induced dyskinesias in Parkinson's disease
  299. Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age
  300. Ethnoterritorial Heterogeneity of Formation of Alcohol Dependence in Native Population of Siberia
  301. Cytochrome P450 System Activity in Alcoholic Patients From Different Ethnic Groups
  302. Brain-derived Neurotrophic Factor in Patients with Affective Disorders
  303. Use of Traditional and Atypical Neuroleptics in Therapy of Psychoses Caused by Use of Synthetic Drugs
  304. Serum Levels of Neurosteroids in Patients with Affective Disorders
  305. New Approaches to the Treatment Alcohol Addiction in Experimental Alcoholism
  306. Role of Benzodiazepine Receptor Plasticity Associated with Neuroactive Steroid's Levels in Patients with Compulsive Craving for Alcohol, New Approaches to Therapy
  307. CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
  308. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility
  309. Analysis of alcohol dependence in indigenous peoples in Northern Siberia.
  310. Association between pathological olfaction, immunological abnormalities and predisposition to substance use
  311. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
  312. P.2.a.008 Correlation between levels of Akt1/GSK-3β signaling pathway proteins and severity of depressive symptoms
  313. P.6.b.006 Carnosine protects blood plasma proteins from damaging effect of acetaldehyde
  314. P.1.g.051 Benzodiazepine receptor system in the brains of rats with experimental alcoholism and treatment effect of a novel anticonvulsant
  315. Proteins of the Akt1/GSK-3β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders
  316. Ratio of Antibodies to Neurotransmitters in the Serum of Students, Occasional Drug Users
  317. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
  318. Effect of Meta-Chlorobenzhydryl Urea (m-ClBHU) on Benzodiazepine Receptor System in Rat Brain During Experimental Alcoholism
  319. Neurophysiological Patterns of Search and Creative Behavior in Patients with Psychoactive Substance-Induced Disorders
  320. Glutamate Concentration in the Serum of Patients with Schizophrenia
  321. Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics
  322. P.6.a.005 Density of thrombocyte benzodiazepine receptors and levels of neuroactive steroid hormones in alcoholic patients
  323. Features of EEG in patients with disorders due to psychoactive substance use during olfactory stimulation
  324. Psychological Defense and Strategies of Coping in Alcohol Dependence and Co-Dependence in Women
  325. 1579 – Migration and mental health of aborigines of siberia: new challenges of old problems
  326. 1581 – Steroid hormones levels in alcohol dependent patients under conditions of social isolation
  327. 491 – Efficacy of original anticonvulsant galodif in treating of patients with compulsive craving to alcohol, associated with alteration levels of steroid hormons
  328. Conformational Stability of Leukocyte Lactate Dehydrogenase in Healthy Men of Different Age
  329. Neurosteroids Dehydroepiandrosterone and Its Sulfate in Individuals with Personality Disorders Convicted of Serious Violent Crimes
  330. P.6.a.006 A new original anticonvulsant decreases alcohol motivation and alters progesterone level in plasma of alcoholic patients
  331. P-14 - Dissociative mechanisms of formation of alcoholism in patients with co-morbid posttraumatic stress disorder
  332. Gender Heteronomy of the Formation of Heroin Addiction in Adolescents
  333. P.6.b.007 Influence of ethanol on synaptic benzodiazepine receptors and forming synapses in embryo's brain of alcoholic women
  334. P.6.b.006 Pharmacokinetic peculiarities of antipirine during treatment of alcoholic patients
  335. P.6.008 Neuropeptide in treatment of alcoholism: effect on psychological functions and lymphocyte apoptosis
  336. Influence of original anticonvulsant on pharmacometabolizing function of liver in patients with alcoholism
  337. P01-12 - Clinical prognosis of associated forms of alcoholism with co-morbid brain impairment
  338. P01-106 - Neuromorphologic and neurochemical regularities of prenatal exposure of developing human brain to alcohol
  339. P.6.a.007 Influence of neuroactive peptidic preparations on apoptosis of immunocompetent cells in alcoholic patients
  340. P.3.c.050 Interaction between polymorphisms of oxidative enzymes and susceptibility to tardive dyskinesia in psychiatric patients
  341. Spontaneous and In Vitro Induced Apoptosis of Lymphocytes and Neutrophils in Patients with Alcohol Dependence
  342. P02-80 - Steroid hormones in patients with personality disorders in conditions of social isolation
  343. PW01-218 - Apoptosis of lymphocytes in alcoholic patients during withdrawal syndrome therapy
  344. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia
  345. P.6.b.004 Apoptosis of immunocompetent cells in patients with alcoholism in dynamic of therapy
  346. P.6.b.006 Peripheral benzodiazepine receptor in platelets of alcoholic patients as a test of efficacy of antialcohol drugs
  347. Effects of Microwave Resonance Therapy on Erythrocyte and Plasma Proteins and Lipids in Alcoholics
  348. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia
  349. P.6.d.012 Immune system in opioid addicts
  350. P.3.d.011 Immunotropic effects of atypical neuroleptics olanzapine and amisulpride
  351. P.6.b.003 Anticraving-therapy of alcoholism in patients with comorbid arterial hypertension: abilities of paroxetine
  352. P.3.c.044 Tardive dyskinesia and polymorphism of dopamine D3, serotonin 2A and 2C receptors in Russian psychiatric inpatients
  353. P.6.b.008 Treatment of alcoholic patients with original anticonvulsant alters alcohol motivation and progesterone level in plasma
  354. Gender-associated patterns of heroin addiction in adolescents
  355. Anticonvulsive properties of M-chlorbenzhydrilurea and prospect of its clinical application
  356. Kinetic of a new drug in patients with alcoholism
  357. The influence of the Antioxidant Carnosin on the intensity of the alcoholic patients pathological addiction to alcohol during rehabilitation period
  358. P.1.b.003 Anticonvulsive drug kinetic in patients with alcoholism
  359. Comorbidity and therapy of affective disturbances in associated forms of alcoholism
  360. Erythrocyte and plasma protein modification in alcoholism: A possible role of acetaldehyde
  361. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and immunity
  362. P.6.063 Clinical and biological effectiveness of anar therapy in opiate addicts
  363. P.1.045 Psychotropic drugs and homeostatic systems: Mechanism of psychoneuroimmunomodulation
  364. P.6.032 Pica, anxiety and addiction: Mechanismsand therapy
  365. P.6.064 Influence of alcohol dependence on oxidative metabolism of xenobiotics in humans
  366. Effect of carnosine on immunocompetent cells from alcoholic patients
  367. Immunity system in alcoholism
  368. COMORBIDITY OF AFFECTIVE DISTURBANCES IN ASSOCIATED FORMS OF ALCOHOLISM.
  369. Effects of antioxidant carnosine on immunity in addiction
  370. IN VITRO EFFECTS OF ETHANOL, ACETALDEHYDE AND FATTY ACID ETHYL ESTERS ON HUMAN ERYTHROCYTES
  371. Therapeutic efficiency coaxil at treatment of alcoholism
  372. EFFECTS OF CARNOSINE AND RELATED COMPOUNDS ON THE STABILITY AND MORPHOLOGY OF ERYTHROCYTES FROM ALCOHOLICS
  373. Efficacy of finlepsin-retard by alcoholism with comorbld brain impairment
  374. Olfaction, nociception and immunity in mental disorders
  375. Sensory systems and immunity in mental disorders